BridgeBio Pharma, Inc. (BBIO)

NASDAQ: BBIO · IEX Real-Time Price · USD
7.19
-0.25 (-3.30%)
May 18, 2022 11:56 AM EDT - Market open
Market Cap1.06B
Revenue (ttm)70.95M
Net Income (ttm)-595.86M
Shares Out147.69M
EPS (ttm)-3.90
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume633,038
Open7.14
Previous Close7.43
Day's Range7.03 - 7.40
52-Week Range4.98 - 65.33
Beta1.09
AnalystsBuy
Price Target26.07 (+262.8%)
Earnings DateMay 5, 2022

About BBIO

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 cli...

IndustryBiotechnology
IPO DateJun 27, 2019
CEONeil Kumar
Employees576
Stock ExchangeNASDAQ
Ticker SymbolBBIO
Full Company Profile

Financial Performance

In 2021, BBIO's revenue was $69.72 million, an increase of 745.14% compared to the previous year's $8.25 million. Losses were -$562.54 million, 25.4% more than in 2020.

Financial Statements

Analyst Forecast

According to 16 analysts, the average rating for BBIO stock is "Buy." The 12-month stock price forecast is 26.07, which is an increase of 262.84% from the latest price.

Price Target
$26.07
(262.84% upside)
Analyst Consensus: Buy
Stock Forecasts

News

BridgeBio (BBIO) Up on Deal With BMY for SHP2 Inhibitor

BridgeBio (BBIO) forms an exclusive partnership with Bristol Myers (BMY) to develop and commercialize its SHP2 inhibitor.

4 days ago - Zacks Investment Research

10 Amazing Stocks Under $10 (Part II)

Because of this stock market crash, some wonderful stocks are super cheap in 2022. Here's a mini-portfolio of innovative companies trading under $10 a share right now.

Other symbols:ADPTDNAFUBOHIMXMSFT
5 days ago - The Motley Fool

BridgeBio Pharma Sells Rare Pediatric Disease Priority Review Voucher for $110 Million and Defers Principal Payment o...

- Entered into a definitive agreement to sell the rare pediatric disease Priority Review Voucher (PRV) it obtained in February 2021 for $110 million

5 days ago - GlobeNewsWire

BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Pot...

- BridgeBio is eligible to receive up to $905 million, including an upfront payment of $90 million, and up to $815 million in additional milestone payments and royalties

6 days ago - GlobeNewsWire

BridgeBio Pharma to Participate in the Bank of America Securities Healthcare Conference

PALO ALTO, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and can...

1 week ago - GlobeNewsWire

BridgeBio Shares Plunge After it Details Out-Licensing Plans For 'Restructuring Initiative'

BridgeBio Pharma Inc (NASDAQ: BBIO) estimates between $23 million to $25 million in restructuring-related costs, including write-offs of long-lived assets, severance and employee-related costs, and exit...

1 week ago - Benzinga

BridgeBio Pharma (BBIO) Reports Q1 Loss, Misses Revenue Estimates

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -5.31% and 80.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

BridgeBio Pharma Reports First Quarter 2022 Financial Results and Business Update

–Completed sale to Sentynl Therapeutics of BridgeBio's NULIBRY™ (Fosdenopterin) for Injection –Updated strategic collaboration with Helsinn Group to develop, manufacture and commercialize infigratinib i...

1 week ago - GlobeNewsWire

BridgeBio Pharma Presents Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyl...

- NT-proBNP, a biomarker of cardiac failure and independent predictor of mortality in ATTR-CM patients, was stable or improving throughout the study. At Month 30, median change from baseline in NT-proBN...

1 month ago - GlobeNewsWire

BridgeBio Pharma to Present Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Am...

PALO ALTO, Calif., March 28, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and c...

1 month ago - GlobeNewsWire

BridgeBio Pharma Posts Updated Data From Muscular Dystrophy Trial, Plots Path To Market

BridgeBio Pharma Inc (NASDAQ: BBIO) has announced data from the Phase 2 study of BBP-418 in patients with limb-girdle muscular dystrophy type 2i (LGMD2i), a group of conditions that cause weakness and w...

2 months ago - Benzinga

BridgeBio Pharma Announces Positive Phase 2 Data for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)

- 43% increase in the ratio of glycosylated alpha-dystroglycan (αDG) to total αDG from baseline were measured across all three dosing cohorts, signifying the oral therapy has the potential to address bo...

2 months ago - GlobeNewsWire

BridgeBio Pharma, Inc. to Host Investor Call to Discuss Phase 2 Data for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)

PALO ALTO, Calif., March 11, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and c...

2 months ago - GlobeNewsWire

BridgeBio Pharma and Sentynl Therapeutics Announce Asset Purchase Agreement for BridgeBio Pharma's NULIBRY™ (Fosdenop...

PALO ALTO and SOLANA BEACH, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company that focuses on genetic diseases an...

2 months ago - GlobeNewsWire

BridgeBio Pharma (BBIO) Reports Q4 Loss, Misses Revenue Estimates

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -21.69% and 61.18%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

BridgeBio Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business Update

–Secured up to $750 million in non-dilutive debt financing in November 2021, extending BridgeBio's financial runway into 2024

2 months ago - GlobeNewsWire

Will BridgeBio Pharma (BBIO) Report Negative Q4 Earnings? What You Should Know

BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

12 biotech stocks to consider buying now as prospects for the sector brighten this year

Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double

3 months ago - Market Watch

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIO

New York, New York--(Newsfile Corp. - February 2, 2022) - Pomerantz LLP is investigating claims on behalf of investors of BridgeBio Pharma, Inc. ("BridgeBio" or the "Company") (NASDAQ: BBIO). Such inves...

3 months ago - Newsfile Corp

BridgeBio Pharma (BBIO) Gains But Lags Market: What You Should Know

BridgeBio Pharma (BBIO) closed the most recent trading day at $9.04, moving +1.01% from the previous trading session.

3 months ago - Zacks Investment Research

BridgeBio (BBIO) Begins Dosing with Gene Therapy in CAH Study

BridgeBio (BBIO) doses the first patient in a phase I/II study evaluating its investigational gene therapy candidate, BBP-631, for treating classic congenital adrenal hyperplasia.

3 months ago - Zacks Investment Research

BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Congenital ...

- If successful, BridgeBio's investigational gene therapy BBP-631 would be the first therapy for CAH to restore the body's hormone and steroid balance by enabling people with CAH to make their own corti...

3 months ago - GlobeNewsWire

BridgeBio (BBIO), Amgen Partner in Advanced Solid Tumors Study

BridgeBio (BBIO) forges an alliance with Amgen to evaluate their respective cancer drugs for the treatment of advanced solid tumors with KRAS G12C mutations.

Other symbols:AMGN
4 months ago - Zacks Investment Research

BridgeBio Announces Clinical Collaboration with Amgen to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, i...

- First clinical combination study of BBP-398 and LUMAKRAS set to evaluate safety and preliminary efficacy in solid tumors with the KRAS G12C mutation

4 months ago - GlobeNewsWire

BridgeBio Pharma (BBIO) Moves 14.6% Higher: Will This Strength Last?

BridgeBio Pharma (BBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increas...

4 months ago - Zacks Investment Research